AVITA Medical, Inc. (NASDAQ:RCEL)
| Market Cap | $388.05M+316.5% |
| Revenue (ttm) | $84.68M+17.0% |
| Net Income | -$36.12M+25.6% |
| EPS | -$1.19+34.3% |
| Shares Out | 24.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 386,982 |
| Open | $15.76 |
| Previous Close | $15.99 |
| Day's Range | $15.50 - $16.26 |
| 52-Week Range | $3.22 - $18.43 |
| Beta | 2.01 |
| Analysts | Buy |
| Price Target | $14.33(-8.26%) |
| Earnings Date | Feb 11, 2027 |
About RCEL
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating RCEL in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 11, 2027Earnings report
$RCEL stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in RCEL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RCEL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RCEL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
RCEL Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New RCEL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RCEL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RCEL
| VTIVanguard Morningstar Total Stock Market ETF | $11.51M |
| VXFVanguard Extended Market ETF | $5.51M |
| IWCiShares Micro-Cap ETF | $1.52M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from RCEL’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst upgrade to Buy, positive clinical trial data showing efficacy, and fair value boost support bullish sentiment on RCEL fundamentals.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| IWC | iShares Micro-Cap ETF | 0.13% |
Weight is the stock’s share of each fund’s holdings.
